Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BGF · 1 trial · 1 indication
Specific image-based airway volume (SiVaw) measured in mL/L. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
Specific image-based airway resistance (siRaw) measured in kPa∙s. Average across lobes, adjusted for lobe volume. Reported as ratio to baseline.
| Arm | Type | Description |
|---|---|---|
| BGF-GFF | EXPERIMENTAL | Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate |
| GFF-BGF | EXPERIMENTAL | Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate |
| Name | Type | Description |
|---|---|---|
| BGF | COMBINATION_PRODUCT | Treatment with Budesonide/Glycopyrronium/FormoterolFumarate |
| GFF | COMBINATION_PRODUCT | Treatment with Glycopyrronium/Formoterol Fumarate |
Inclusion Criteria: Subject must be 40 years to ≤80 years of age inclusive, at the time of signing the informed consent form at Visit 1. * COPD Diagnosis: Subjects with an established clinical history of COPD * Screening clinical laboratory tests must be acceptable to the Investigator. * Screening...
BGF is an investigational small molecule being developed for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is currently in Phase 3 clinical development, though the specific trial data provided has been completed. BGF is not approved and remains under investigation for this respiratory condition.
BGF is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical research on BGF for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
BGF is in Phase 3 clinical development for Chronic Obstructive Pulmonary Disease (COPD). The Phase 3 trial listed has been completed, but BGF remains an investigational drug and is not yet approved for any use.
BGF has one completed Phase 3 clinical trial registered under NCT03836677, titled 'A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.' The trial enrolled 23 participants in Belgium and the Netherlands.
No, BGF is not the same as GFF. In the clinical trial NCT03836677, BGF and GFF are evaluated as separate treatments for Chronic Obstructive Pulmonary Disease (COPD). The study compares the effects of BGF and GFF on airway volumes and resistance.
The BGF Phase 3 trial NCT03836677 is a randomized, double-blind, controlled study in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It enrolled 23 adults aged 40 years and older, of all sexes, at sites in Belgium and the Netherlands. The trial has been completed.